#USA #CARY #OncoHost #PROphet #CAP Accreditation

OncoHost's Cary Laboratory Achieves CAP Accreditation

OncoHost, a pioneering technology firm transforming the landscape of precision medicine, has recently announced a significant milestone in its journey toward enhanced patient care. The company's high-throughput proteomics laboratory located in Cary, North Carolina, has garnered accreditation from the College of American Pathologists (CAP). This prestigious recognition underscores OncoHost's unwavering commitment to maintaining the highest standards of quality and safety in laboratory practices.

CAP is a globally recognized leader in laboratory quality assurance, making this accreditation a noteworthy achievement for OncoHost's Cary facility, which stands out as a specialized establishment focusing on human host response analysis. This laboratory is among the few that operate on an industrial level expressly dedicated to this purpose, enhancing its uniqueness in the field of precision diagnostics.

Dr. Amir Gelman, the Director of Laboratory Operations at OncoHost, expressed pride in this accomplishment, stating, “We are honored to achieve CAP accreditation, a testament to our commitment to delivering the highest quality diagnostics. This recognition reflects our dedication to precision and stringent compliance, ensuring healthcare providers and patients can trust the results guiding critical decisions in their cancer care.”

At the core of OncoHost's innovative approach lies its proprietary PROphet® platform. This advanced plasma-based proteomic pattern recognition tool melds systems biology, bioinformatics, and artificial intelligence to elevate clinical decision-making. By utilizing just a single pre-treatment blood sample, PROphet® scrutinizes patterns across approximately 7,000 proteins, yielding a clinically validated metric known as the PROphet® score. This score effectively indicates a patient's likelihood of benefiting from various treatment modalities, thus paving the way for tailored healthcare strategies that resonate with individual patient biology.

The capability of PROphet® to predict potential benefits from cancer therapies—whether immunotherapy alone or in conjunction with chemotherapy—empowers healthcare providers to make informed decisions, thereby minimizing unnecessary treatments and maximizing patient survival rates.

OncoHost's CEO, Dr. Ofer Sharon, emphasized the significance of the CAP accreditation, stating, “This CAP accreditation is a pivotal milestone for OncoHost as we advance our mission to bring the highest standards of quality and innovation to precision oncology. I am incredibly proud of our dedicated team, whose expertise and commitment to excellence made this achievement possible.”

The rigorous CAP Laboratory Accreditation Program enhances patient safety through meticulous peer evaluation and inspection, ensuring labs meet stringent standards in quality control, safety, personnel qualifications, equipment maintenance, and operational management. OncoHost's Cary lab successfully demonstrated full compliance with these demanding criteria, solidifying its place in advancing cancer diagnostics and patient care.

OncoHost, headquartered in both Binyamina, Israel, and Cary, North Carolina, remains steadfast in its vision to redefine precision medicine. The company’s innovative PROphet® platform is presently applied in guiding first-line immunotherapy decisions for non-small cell lung cancer (NSCLC) through the PROphetNSCLC™ test. This test not only offers vital insights to clinicians but also significantly enhances overall patient survival rates.

The company is supported by a vast prospective clinical trial, engaging over 40 sites and gathering data from around 1,700 patients worldwide. With an adept team consisting of entrepreneurs and industry experts, OncoHost is poised to lead the charge in precision diagnostics and biomarker development into new realms of success.

For further details about OncoHost and its pioneering work in precision medicine, interested parties are encouraged to visit OncoHost's website or follow them on popular social media platforms including LinkedIn, Twitter, Facebook, and YouTube.